The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Abstract
MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [32]
In the citing paper
“Nutlin-3a had the strongest activity, and its binding activity with MDM2 reached 90 nM.”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“At 200 mg/kg, twice a day, 20 days after oral administration of Nutlin-3a, the tumor growth inhibition rate reached 90%, with no obvious side effects [20].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“Moreover, others have shown that inhibition of MDM2 binding to p53 or p73α appears to be more effective at promoting p53- and p73α-mediated apoptosis in cancer cells compared with normal cells.19,45”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [45]
In the citing paper
“Nutlin-3a is a small molecule, which binds to the N-terminal hydrophobic pocket of Mdm2 and blocks protein-protein interactions (PPIs) between Mdm2 and p53 (10).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [10]
In the citing paper
“It has been reported that a consequence of Nutlin treatment is elevated Mdm2 protein levels, and this occurs in cells with or without p53 (6,8).”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nutlin-3 is a small molecule inhibitor of Mdm2/p53 interaction that can induce apoptosis in cancer cells through activation of p53.”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nonmalignant tissues tolerate inhibition of Mdm2, and no overt toxicity was observed in preclinical in vivo models.9,11”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [9]
In the citing paper
“For example, small molecule antagonism of the Mdm2–p53 interaction promotes p53-dependent tumor regression in murine models [102,103].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [103]
In the citing paper
“Small-molecule PPI antagonists that disrupt the p53–MDM2 interaction have been identified, including nutlin 3a96 and MI-219 (Ref. 97).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [96]
In the citing paper
“To utilize MDM2 for the PROTAC system, the discovery of nutlins, small molecules that bind MDM2 at the p53 interaction interface, was a crucial step [66].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [66]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Research works printed but not linked: 3
- D. Freedman, A. J. Levine, Cell. Mol. Life Sci.5, 96 (1999).
- R. Zhang, H. Wang, Methods Mol. Med.85, 205 (2003).
- L. T. Vassilevet al., Anticancer Drug Des.13, 359 (2001).
Cited by
Sorted by citations
Items 901–1,000 of 1,103
A Resource-Efficient and Highly Flexible Procedure for a Three-Component Synthesis of 2-Imidazolines
Elders, N., Schmitz, R. F., de Kanter, F. J. J., Ruijter, E., Groen, M. B., & Orrù, R. V. A. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo070840x · Cited by 93
Jin, J.-Z., Lin, G., Huang, H., Xu, D. M., Yu, H., Ma, X., Zhu, L., Ma, D., & Jiang, H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.7730 · Cited by 96
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Tumor suppressor protein (p)53, is a regulator of NF-κB repression by the glucocorticoid receptor
Murphy, S. H., Suzuki, K., Downes, M., Welch, G. L., De Jesus, P., Miraglia, L. J., Orth, A. P., Chanda, S. K., Evans, R. M., & Verma, I. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114420108 · Cited by 93
Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 96
Johnson, D. K., & Karanicolas, J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002951 · Cited by 92
Targeting MDM2 for novel molecular therapy: Beyond oncology
Wang, W., Qin, J., Rajaei, M., Li, X., Yu, X., Hunt, C., & Zhang, R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21637 · Cited by 90
Apoptotic Pathways in Tumor Progression and Therapy
Melet, A., Song, K., Bucur, O., Jagani, Z., Grassian, A. R., & Khosravi‐Far, R. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_4 · Cited by 92
Quantitative Lid Dynamics of MDM2 Reveals Differential Ligand Binding Modes of the p53-Binding Cleft
Showalter, S. A., Bruschweiler‐Li, L., Johnson, E., Zhang, F., & Brüschweiler, R. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800201j · Cited by 91
The p53 tumor suppressor protein regulates hematopoietic stem cell fate
Asai, T., Liu, Y., Bae, N., & Nimer, S. D. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22561 · Cited by 102
Porter, J. R., Fisher, B. E., & Batchelor, E. (2016) · Cell Systems · doi:10.1016/j.cels.2016.03.006 · Cited by 90
Liver stage malaria infection is controlled by host regulators of lipid peroxidation
Kain, H. S., Glennon, E. K. K., Vijayan, K., Arang, N., Douglass, A. N., Fortin, C. L., Zuck, M., Lewis, A. J., Whiteside, S. L., Dudgeon, D. R., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0338-1 · Cited by 91
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91
mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19
Ramaiah, M. J. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100765 · Cited by 90
Therapeutic targeting of apoptosis pathways in cancer
Ziegler, D. S., & Kung, A. L. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f310f6 · Cited by 92
LaRusch, G. A., Jackson, M. W., Dunbar, J. D., Warren, R. S., Donner, D. B., & Mayo, L. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2710 · Cited by 89
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie · doi:10.1002/ange.201412070 · Cited by 90
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 91
Koster, S., Gurumurthy, R. K., Kumar, N., Prakash, P. G., Dhanraj, J., Bayer, S., Berger, H., Kurian, S. M., Drabkina, M., Mollenkopf, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28569-1 · Cited by 93
Klein, S., McCormick, F. P., & Levitzki, A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1651 · Cited by 89
Ahmed, K. M., Zhang, H., & Park, C. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3537 · Cited by 95
Dynamite: a simple way to gain insight into protein motions
Barrett, C. P., Hall, B. A., & Noble, M. E. M. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019171 · Cited by 89
Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress
Peltonen, K., Colis, L. C., Liu, H., Jäämaa, S., Zhang, Z., af Hällström, T., Moore, H. M., Sirajuddin, P., & Laiho, M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0256 · Cited by 90
Tsukamoto, S., Takeuchi, T., Rotinsulu, H., Mangindaan, R. E. P., van Soest, R. W. M., Ukai, K., Kobayashi, H., Namikoshi, M., Ohta, T., & Yokosawa, H. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.110 · Cited by 90
Ladds, M. J. G. W., van Leeuwen, I. M. M., Drummond, C. J., Chu, S., Healy, A. R., Popova, G., Fernández, A. P., Mollick, T., Darekar, S. D., Sedimbi, S. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03441-3 · Cited by 89
Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance
Videira, M., Reis, R. L., & Brito, M. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.011 · Cited by 93
Aberrant regulation of FBW7 in cancer
Wang, L., Ye, X., Liu, Y., Wei, W., & Wang, Z. P. (2014) · Oncotarget · doi:10.18632/oncotarget.1859 · Cited by 91
Targeting recognition surfaces on natural proteins with peptidic foldamers
Checco, J. W., & Gellman, S. H. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.06.014 · Cited by 88
Laudato, S., Patil, N., Abba, M. L., Leupold, J. H., Benner, A., Gaiser, T., Marx, A., & Allgayer, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.30854 · Cited by 90
Bertamino, A., Soprano, M., Musella, S., Rusciano, M. R., Sala, M., Vernieri, E., Sarno, V. D., Limatola, A., Carotenuto, A., Cosconati, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400311n · Cited by 86
Rokudai, S., Aikawa, Y., Tagata, Y., Tsuchida, N., Taya, Y., & Kitabayashi, I. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805101200 · Cited by 95
Verma, S., Grover, S., Tyagi, C., Goyal, S., Jamal, S., Singh, A. P., & Grover, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149014 · Cited by 90
p53-dependent SIRT6 expression protects Aβ42-induced DNA damage
Jung, E. S., Choi, H., Song, H., Hwang, Y. J., Kim, A., Ryu, H., & Mook‐Jung, I. (2016) · Scientific Reports · doi:10.1038/srep25628 · Cited by 91
Schlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90
CRISPR-Cas9–based target validation for p53-reactivating model compounds
Wanzel, M., Vischedyk, J. B., Gittler, M. P., Gremke, N., Seiz, J. R., Hefter, M., Noack, M., Savai, R., Mernberger, M., Charles, J. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1965 · Cited by 87
Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis
Gupta, I., Singh, K., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00011 · Cited by 88
Santoro, A., Vlachou, T., Luzi, L., Melloni, G. E. M., Mazzarella, L., D’Elia, E., Xieraili, A., Pasi, C. E., Reavie, L. B., Bonetti, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.071 · Cited by 88
Kelch-like proteins: Physiological functions and relationships with diseases
Shi, X., Xiang, S., Cao, J., Zhu, H., Yang, B., He, Q., & Ying, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104404 · Cited by 92
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 99
Dastidar, S. G., Lane, D. P., & Verma, C. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804289g · Cited by 87
Wunderlich, K., Mayer, D., Ranadheera, C., Holler, A.-S., Mänz, B., Arnold, M., Chase, G. P., Tegge, W. J., Frank, R., Kessler, U., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007517 · Cited by 88
Helen, S., Horne, G. A., Bastow, S., & Chevassut, T. J. T. (2013) · Cancer Medicine · doi:10.1002/cam4.146 · Cited by 91
NAD+ Modulates p53 DNA Binding Specificity and Function
McLure, K. G., Takagi, M., & Kastan, M. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9958-9967.2004 · Cited by 89
Vaseva, A. V., Marchenko, N. D., & Moll, U. M. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8596 · Cited by 91
Teoh, N., Dan, Y. Y., Swisshelm, K. L., Lehman, S. L., Wright, J. H., Haque, J. A., Gu, Y., & Fausto, N. (2008) · Hepatology · doi:10.1002/hep.22194 · Cited by 90
Yoshimura, M., Ishizawa, J., Ruvolo, V. R., Dilip, A., Quintás‐Cardama, A., McDonnell, T. J., Neelapu, S. S., Kwak, L. W., Shacham, S., Kauffman, M. G., et al. (2014) · Cancer Science · doi:10.1111/cas.12430 · Cited by 90
Bettayeb, K., Baunbæk, D., Delehouzé, C., Loaëc, N., Hole, A. J., Baumli, S., Endicott, J., Douc‐Rasy, S., Bénard, J., Oumata, N., et al. (2010) · Genes & Cancer · doi:10.1177/1947601910369817 · Cited by 91
Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities
Barboza, J., Iwakuma, T., Terzian, T., El‐Naggar, A. K., & Lozano, G. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2079 · Cited by 91
CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases
Sharma, P. K., & Nag, A. (2014) · Open Biology · doi:10.1098/rsob.130217 · Cited by 88
Tsukamoto, S., Yoshida, T., Hosono, H., Ohta, T., & Yokosawa, H. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.052 · Cited by 89
Böhlig, L., Friedrich, M., & Engeland, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq796 · Cited by 85
Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0338 · Cited by 87
Love, I. M., Šekaric, P., Shi, D., Grossman, S. R., & Androphy, E. J. (2012) · Cell Cycle · doi:10.4161/cc.20864 · Cited by 89
AHNAK controls 53BP1-mediated p53 response by restraining 53BP1 oligomerization and phase separation
Ghodke, I., Remišová, M., Furst, A., Kilic, S., Reina‐San‐Martin, B., Poetsch, A. R., Altmeyer, M., & Soutoglou, E. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.010 · Cited by 93
A non-canonical role for a small nucleolar RNA in ribosome biogenesis and senescence
Cheng, Y., Wang, S., Zhang, H., Lee, J.-S., Ni, C., Guo, J., Chen, E., Wang, S., Acharya, A., Chang, T.-C., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.019 · Cited by 92
Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 89
Stommel, J. M., & Wahl, G. M. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1522 · Cited by 90
Monitoring the Effects of Antagonists on Protein−Protein Interactions with NMR Spectroscopy
D’Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh, M., & Holak, T. A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052143x · Cited by 88
Miniature Protein Inhibitors of the p53–hDM2 Interaction
Kritzer, J. A., Zutshi, R., Cheah, M. T., Ran, F. A., Webman, R. B., Wongjirad, T. M., & Schepartz, A. (2006) · ChemBioChem · doi:10.1002/cbic.200500324 · Cited by 90
A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly
Krastev, D. B., Slabicki, M. M., Paszkowski‐Rogacz, M., Hubner, N. C., Junqueira, M., Shevchenko, A., Mann, M., Neugebauer, K. M., & Buchholz, F. (2011) · Nature Cell Biology · doi:10.1038/ncb2264 · Cited by 88
Restoration of wild‐type p53 function in human cancer: Relevance for tumor therapy
Bossi, G., & Sacchi, A. (2007) · Head & Neck · doi:10.1002/hed.20529 · Cited by 86
Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H. E., Künkele, A., Eggert, A., Schulte, J. H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23409 · Cited by 85
Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment
Gu, L., Zhang, H., Liu, T., Zhou, S., Du, Y., Xiong, J., Yi, S., Qu, C.-K., Fu, H., & Zhou, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.015 · Cited by 86
Small-molecule inhibitors of MDM2 as new anticancer therapeutics
Dickens, M. P., Fitzgerald, R. P., & Fischer, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.003 · Cited by 90
Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers
Tornesello, M. L., Annunziata, C., Tornesello, A. L., Buonaguro, L., & Buonaguro, F. M. (2018) · Cancers · doi:10.3390/cancers10070213 · Cited by 87
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 86
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas
Valentin-Vega, Y. A., Barboza, J., Chau, G. P., El‐Naggar, A. K., & Lozano, G. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.005 · Cited by 85
Fontaine, F. R., Overman, J. P., & François, M. (2015) · Cell Regeneration · doi:10.1186/s13619-015-0015-x · Cited by 89
Deben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 86
Misiewicz-Krzemińska, I., Sarasquete, M. E., Quwaider, D., Krzemiński, P., Ticona, F. V., Paíno, T., Delgado, M., Aires, A., Ocio, E. M., García‐Sánz, R., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.070011 · Cited by 85
Targeting apoptosis in acute myeloid leukaemia
Cassier, P. A., Castets, M., Belhabri, A., & Vey, N. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.281 · Cited by 86
Ueda, T., Tamura, T., Kawano, M., Shiono, K., Hóbor, F., Wilson, A. J., & Hamachi, I. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00703 · Cited by 85
Zhang, H., Xu, J., Long, Y., Maimaitijiang, A., Su, Z., Li, W., & Li, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312928 · Cited by 97
Long, J., Parkin, B. L., Ouillette, P. D., Bixby, D. L., Shedden, K., Erba, H. P., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 87
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Kim, K. W., Albert, J. M., Hallahan, D. E., & Lü, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 83
Yang, J., Ahmed, A., Poon, E., Perusinghe, N. P., Brandon, A. D. H., Box, G., Valenti, M. R., Eccles, S. A., Rouschop, K. M. A., Wouters, B. G., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00959-08 · Cited by 86
Strategien zur Modulation von Protein‐Protein‐Wechselwirkungen mit synthetischen Substanzen
Yin, H. H., & Hamilton, A. D. (2005) · Angewandte Chemie · doi:10.1002/ange.200461786 · Cited by 87
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M. G. A., Starzetz, T., Harter, P. N., Abhari, B. A., Fulda, S., et al. (2015) · Scientific Reports · doi:10.1038/srep08202 · Cited by 86
Nongenotoxic p53 Activation Protects Cells against S-Phase–Specific Chemotherapy
Kranz, D., & Dobbelstein, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1527 · Cited by 85
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 87
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Chang, Y.-W., Tseng, C.-F., Wang, M.-Y., Chang, W.-C., Lee, C.-C., Chen, L.-T., Hung, M.-C., & Su, J.-L. (2016) · Oncogene · doi:10.1038/onc.2015.214 · Cited by 82
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
Targeted and nontargeted effects of ionizing radiation that impact genomic instability
Maxwell, C. A., Fleisch, M. C., Costes, S. V., Erickson, A. C., Boissière, A., Gupta, R., Ravani, S. A., Parvin, B., & Barcellos-Hoff, M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1212 · Cited by 89
Shahbandi, A., Chiu, F.-Y., Ungerleider, N., Kvadas, R. M., Mheidly, Z., Sun, M. J. S., Tian, D., Waizman, D. A., Anderson, A. Y., Machado, H. L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00466-y · Cited by 88
Pharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 97
Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction
González, A. Z., Eksterowicz, J. E., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Duquette, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401767k · Cited by 87
p53 as a target for anti-cancer drug development
Bouchet, B. P., de Fromentel, C. C., Puisieux, A., & Galmarini, C. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.10.005 · Cited by 90
Yu, Y., Wang, Y., Ren, X., Tsuyada, A., Li, A., Liu, L. J., & Wang, S. E. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0362 · Cited by 86
Silva, T. F. S., Martins, L. M. D. R. S., da Silva, M. F. C. G., Fernandes, A. R., Silva, A., Borralho, P. M., Santos, S., Rodrigues, C. M. P., & Pombeiro, A. J. L. (2012) · Dalton Transactions · doi:10.1039/c2dt11577h · Cited by 84
Bauleth‐Ramos, T., Shahbazi, M., Liu, D., Fontana, F., Correia, A., Figueiredo, P., Zhang, H., Martins, J. P., Hirvonen, J. J., Granja, P. L., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703303 · Cited by 84
Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
Secchiero, P., Melloni, E., di Iasio, M. G., Tiribelli, M., Rimondi, E., Corallini, F., Gattei, V., & Zauli, G. (2009) · Blood · doi:10.1182/blood-2008-11-187708 · Cited by 83
Li, Y., Rodewald, L. W., Hoppmann, C., Wong, E. T., Lebreton, S., Šafář, P., Pátek, M., Wang, L., Wertman, K. F., & Wahl, G. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.058 · Cited by 84
Gomez-Monterrey, I. M., Bertamino, A., Porta, A., Carotenuto, A., Musella, S., Aquino, C., Granata, I., Sala, M., Brancaccio, D., Picone, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100838z · Cited by 83
Novel strategies to target the ubiquitin proteasome system in multiple myeloma
Lub, S., Maes, K., Menu, E., Bruyne, E. D., Vanderkerken, K., & Valckenborgh, E. V. (2015) · Oncotarget · doi:10.18632/oncotarget.6658 · Cited by 86
Metadata
- Authors
- Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A.
- Affiliations
- Department of Discovery Oncology, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, USA.
- Corresponding author
- Vassilev, Lyubomir T.
- Venue
- Science
- Published
- 2004-02-06
- Volume
- 303
- Issue
- 5659
- Pages
- 844-848
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097933346
- Cited by
- 4,661
- References
- 21
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 169 · 2023: 203 · 2022: 204 · 2021: 199 · 2020: 226 · 2019: 212 · 2018: 216 · 2017: 209 · 2016: 258 · 2015: 248 · 2014: 296 · 2013: 273 · 2012: 265
- FWCI
- 83.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, small molecule antagonists, p53 stabilization, p53-MDM2 interaction, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts, crystal structure
- MeSH terms
- Animals, Binding Sites, Cell Cycle, Cell Division, Cell Line, Cell Survival, Crystallization, Dose-Response Relationship, Drug, Humans, Imidazoles, Mice, Nude, Models, Molecular, Molecular Weight, Neoplasm Transplantation, Neoplasms, Experimental, Nuclear Proteins, Phosphorylation, Piperazines, Protein Conformation, Proto-Oncogene Proteins, Stereoisomerism, Transplantation, Heterologous, Gene Expression, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Crystallography, X-Ray, NIH 3T3 Cells, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Mice, Proto-Oncogene Proteins c-mdm2, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
